Back to Trades
Total Value
$1.7M
Net $1.7M sold
Filing Date
Jul 9, 2026
2 transactions
Sales
$1.7M
2 transactions
Trade Summary
On Jul 7, 2026, BENNETT C FRANK, EVP, Chief Scientific Officer, sold $1.7M of IONIS PHARMACEUTICALS INC (IONS) across 2 transactions. The filing covers Common Stock and reflects net selling of $1.7M. Reported prices ranged from $83.58 to $85.46. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- IONIS PHARMACEUTICALS INC
- Ticker Symbol
- IONS
- CIK
- 0000874015
Insider Information
- Name
- BENNETT C FRANK
- Role
- EVP, Chief Scientific Officer
- Location
- CARLSBAD, CA
Filing Details
- Filing Date
- Jul 9, 2026
- Transaction Date
- Jul 7, 2026
- Accession Number
- 0000874015-26-000239
- Form Type
- 4
- Net Trading Amount
- -$1.7M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | 5,536 | $83.58 | Sale | $462.7K |
| Jul 7, 2026 | Common Stock | 15,000 | — | Other | — |
| Jul 7, 2026 | Common Stock | 15,000 | $85.46 | Sale | $1.3M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | IONS derivative | 15,000 | — | Other | — |
Want live alerts when BENNETT C FRANK trades again?
Download Insider Trades to track IONS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026.
- (F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.070 to $84.065 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- (F3)Represents a transfer of 15,000 shares of common stock from direct ownership to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust Dated 3/12/2008, of which the reporting person is the co-trustee with spouse.
- (F4)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.015 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- (F5)Restricted Stock Unit vested on January 15, 2026. Upon vesting, the restricted stock unit was paid out in whole shares of Ionis common stock.